“CRISPR babies” have been on everyone’s lips since news broke last week that Chinese scientists claimed they had produced the first full-term gene edited humans. While it raises a number of questions about the scientific process and ethics, investors should also be aware of how far the technology has come in the last few years, as well as where the many other ongoing CRISPR and gene editing projects will take us in the future.
To read this Market Insight, you’ll need to sign in
If you don’t have a subscription, sign up or start a free trial .
